News 15/02/2022


Milan, Italy- (WEBSITE ANNOUNCEMENT) –  Deenova, announced today that following its successful market entry in UK with the 15 year contract award for the hospital pharmacy at the  University Hospitals of Leicester NHS Trust, and to consolidate its commercial operations, Deenova appointed Andrew Lyon as UK Commercial Director.

Andrew Lyon brings with him more than 20 years of commercial leadership and position in companies such as EksoBionics, Omnicell, Medtrade and Bard(Now BD).

Andrew Lyon stated “I’m delighted that Deenova is investing in the UK market. Unit dose technology represents a pivotal moment for medication management within the NHS, offering great opportunity for improvement in patient safety, reductions in waste and minimising the burden on nurses, enabling them to focus more on the patient. This comes at a time when the NHS is under immense pressure, so I’m very proud to be able to contribute to such an important mission.”

“I am excited to have Andy joining our team to lead our commercial activities in the UK”, declared Christophe Jaffuel, Chief commercial Officer of Deenova. “Deenova successful entry in the UK  last year with the 15 year service contract at the  University Hospitals of Leicester, the 4th largest NHS trust in UK, shows the potential  of our solutions in this Market, and I am confident that Andy will be successful in his new role.”

In August 2021 the company reported it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market.

Deenova solutions benefits were evidenced by the report issued by the East Midlands Academic Health Science Network (AHSN) undertaking an 18 month evaluation. The published results included: 25% reduction in the consumption (and costs) of medicines; 40% reduction in the number of items held in the ward stock cupboard, 60% reduction in medicines wastage, and a reduction in missed doses due to medicine not available on wards from 10% to 1.2%, amongst other patient safety and economic benefits.


Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova‘s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.